Pharmacokinetics and thrombolytic effects of the recombinant tissue-type plasminogen activator in horses.

Summary

# Editorial Summary Alteplase (recombinant tissue-type plasminogen activator) has clinical potential for treating thromboembolic disease in horses, but dosing guidance and efficacy data specific to equine patients have been limited. Bäumer and colleagues investigated both the thrombolytic efficacy of alteplase in laboratory-generated equine clots and its pharmacokinetic behaviour in vivo, administering a single 1 mg/kg intravenous dose over 30 minutes to six healthy horses whilst measuring plasma rt-PA concentrations, coagulation variables, haematology and clinical parameters over the subsequent 48 hours. In vitro testing demonstrated measurable clot lysis over four hours, whilst the pharmacokinetic data established rapid plasma clearance and defined the absorption–distribution–elimination profile needed for clinical dosing protocols. These findings provide the foundational safety and efficacy framework for considering alteplase as a thrombolytic agent in equine practice, though further investigation into optimal dosing regimens and clinical efficacy in naturally occurring thrombotic conditions would be required before routine recommendation.

Read the full abstract on PubMed

Key Findings

• •Recombinant tissue-type plasminogen activator (alteplase) demonstrated thrombolytic effects on in vitro equine thrombi with measurable lysis over 4 hours
• •Single intravenous dose of 1 mg/kg alteplase was administered and tolerated in 6 healthy horses with pharmacokinetic measurements over 300 minutes
• •Coagulation variables, blood count and clinical parameters were monitored for 48 hours post-treatment to assess safety profile

Conditions Studied